NeuroMetrix acquisition by electroCore completes, enhancing bioelectronic portfolio
Deal News | May 05, 2025 | EIN
In December, bioelectronic technology company electroCore completed the acquisition of NeuroMetrix, a neurotechnology solution provider recognized for its cloud-enabled wearable neuromodulation solution, Quell. This acquisition excludes NeuroMetrix's DPNCheck, which is targeted for divestment, as part of a deal involving a $4.49 per share cash payment plus a contingent value right for shareholders. This acquisition strengthens electroCore's presence in non-invasive therapies within the VA Hospital System, expanding its market reach, particularly in fibromyalgia and chronic pain solutions.
Sectors
- Healthcare Technology
- Medical Devices
Geography
- United States – The companies involved, electroCore and NeuroMetrix, are based in the United States, and the FDA approval mentioned also pertains to U.S. regulation.
Industry
- Healthcare Technology – The article involves bioelectronic and neurotechnology solutions for treating chronic pain and fibromyalgia, which are part of the healthcare technology industry.
- Medical Devices – NeuroMetrix produces wearable neuromodulation solutions, making this a relevant classification in the medical devices sector.
Financials
- 4.49 – Each share of NeuroMetrix common stock was converted to a cash payment of $4.49, plus a contingent value right (CVR).
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| electroCore | Acquiring Company | Company | A bioelectronic technology company acquiring NeuroMetrix to enhance its portfolio in non-invasive therapies. |
| NeuroMetrix | Target Company | Company | A provider of neurotechnology solutions known for its Quell platform, now acquired by electroCore. |
| Dan Goldberger | CEO of electroCore | People | Chief Executive Officer of electroCore, commenting on the acquisition strategy. |